CERUS CORP — Investor Relations & Filings
Filings indexed
1,009
across all filing types
Latest filing
2026-04-30
Interim / Quarterly Rep…
Country
US
United States of America
Listing
US
CERS
Cerus Corporation is a biomedical products company dedicated to safeguarding the world's blood supply. The company develops and commercializes the INTERCEPT Blood System, a pathogen inactivation technology designed to reduce the risk of transfusion-transmitted infections. The system inactivates a broad spectrum of viruses, bacteria, parasites, and leukocytes in donated blood components. It is used for platelets and plasma, with a system for red blood cells in development. Cerus provides its technology to blood centers and hospitals, aiming to establish a new standard of care for blood safety.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 10-Q - CERUS CORP (0001020214) (Filer) | 2026-04-30 | English | |
| ARS - CERUS CORP (0001020214) (Filer) | 2026-04-22 | English | |
| DEF 14A - CERUS CORP (0001020214) (Filer) | 2026-04-22 | English | |
| 8-K - CERUS CORP (0001020214) (Filer) | 2026-04-21 | English | |
| SCHEDULE 13G - CERUS CORP (0001020214) (Subject) | 2026-03-24 | English | |
| 10-K - CERUS CORP (0001020214) (Filer) | 2026-03-02 | English |
Browse filings by year
18 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
9 filings
| |||||
| 39228045 | 10-Q - CERUS CORP (0001020214) (Filer) | 2026-04-30 | English | ||
| 35304984 | ARS - CERUS CORP (0001020214) (Filer) | 2026-04-22 | English | ||
| 35305171 | DEF 14A - CERUS CORP (0001020214) (Filer) | 2026-04-22 | English | ||
| 34915401 | 8-K - CERUS CORP (0001020214) (Filer) | 2026-04-21 | English | ||
| 33035200 | SCHEDULE 13G - CERUS CORP (0001020214) (Subject) | 2026-03-24 | English | ||
| 32885386 | 10-K - CERUS CORP (0001020214) (Filer) | 2026-03-02 | English | ||
| 32885385 | 8-K - CERUS CORP (0001020214) (Filer) | 2026-03-02 | English | ||
| 26298646 | 8-K Filing | 2026-01-23 | English | ||
| 26298636 | 8-K Filing | 2026-01-12 | English | ||
|
2025
6 filings
| |||||
| 10764514 | 4 | 2025-11-26 | English | ||
| 10764525 | Regulatory Filings 2025 | 2025-11-24 | English | ||
| 10764515 | Major Shareholding Notification 2025 | 2025-11-14 | English | ||
| 10764521 | 10-Q | 2025-11-06 | English | ||
| 10764523 | 8-K | 2025-11-06 | English | ||
| 10764526 | 4 | 2025-08-25 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
BriaCell Therapeutics Corp.
Developing targeted cellular immunotherapies using whole-ce…
|
BCTX | CA | Manufacturing |
|
BridgeBio Oncology Therapeutics, Inc.
Clinical-stage biopharma developing inhibitors for genetica…
|
BBOT | US | Manufacturing |
|
BridgeBio Pharma, Inc.
Develops transformative medicines for genetic diseases and …
|
BBIO | US | Manufacturing |
|
Brightgene Bio-Medical Technology Co., Ltd.
Research-driven developer of complex APIs, high-end generic…
|
688166 | CN | Manufacturing |
|
BRIGHT MINDS BIOSCIENCES INC.
Develops selective serotonin agonists for neurological and …
|
DRUG | US | Manufacturing |
|
BrightPath Biotherapeutics Co., Ltd.
A clinical-stage biopharma company developing cancer immuno…
|
4594 | JP | Manufacturing |
|
Brii Biosciences Limited
Developing first-in-class therapies targeting infectious an…
|
2137 | KY | Manufacturing |
|
BRISTOL MYERS SQUIBB CO
A global biopharmaceutical company that discovers, develops…
|
BMY | US | Manufacturing |
|
BROOKS LABORATORIES LIMITED
Pharmaceutical manufacturer specializing in CRAMS and diver…
|
BROOKS | IN | Manufacturing |
|
BUKWANG PHARMACEUTICAL IND CO.,LTD
An R&D-focused company developing drugs for CNS disorders a…
|
003000 | KR | Manufacturing |
CERUS CORP via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/33349/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=33349 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=33349 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=33349 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 33349}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for CERUS CORP (id: 33349)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.